Neurodoc's Blog : Latest entries

It appears now that P&P is recording trades at market open (hooray!) chance now to see how effective a weekly trading strategy might be. (Right now I've got nowhere to go but up). JW

Well, debate for this year's Sept is over--bulls won. Seasonal-average watchers can now say, OK, but wait til next year!! Happy autumn investing. JW

MAPP's Levadex to be presented at the IHS conference--looks very promising for migraine as alternative to triptans. See www.mappharma.com.

(I'm looking forward to my "biggest loser" not being that!)

Happy investing. JW

Bad enough that our picks can't be credited at the market open...I found some missing from last week--and they are still in the "pending" section from 8/9! (Beginnning to feel like Rodney Dangerfield!) In the real world 2 gained; the other 2 were flat. No telling when they'll actually join the portfolio! Ah well, such is life in Betaville.

looks like 1-2 so far. I called them prematurely earlier in this rally and bought short ETF's and lost some of the gain of the continued rally. 3 clear distribution days signals caution (get off margin)--4-5 look out for downturn and get mental stop losses in place. The volatile stocks on my earnings estimate screens are taking hits, as may be the RUT and SML . I'm still buying for a possible continued rally but may start to raise some cash if stop losses dominate over gains.

My new morning buys today from Research Wizard screening will look great based on Fri close on RW backtesting (assuming they hold up the rest of the week), but from today's open less spectacular because they gapped up:

Stock------My return today-------What RW records from Fri

FCX ........-.38%..........................2.7%
GS.............1.24...........................2.03
HA..............2.24...........................3.25
NNI.............0.51............................0.98
UFPI.....…

Here's a blurb from Medscape--MDVN still looks good, but the science is murky:

July 15, 2009 (Vienna, Austria) — Despite promising clinical effects in the treatment of mild to moderate Alzheimer's disease (AD), new animal research shows that dimebolin (Dimebon, Medivation) increases beta-amyloid (Aβ) levels, raising new questions about whether pursuing the development of antiamyloid therapies is the best way go.

Presented here at the Alzheimer's Association 2009 International Conferen…

Big market moves today, and one of my earnings estimate revision screens showed a couple of strange new hits:

SGY: earning estimate revision 185%, but Zacks (long-term) sell (poor competitive; high debt) but Zacks 2 rating (short-term buy)--short-term play!

PJC: (Piper Jaffray a buy??) earn estimate revision 138% most accurate 983%! but pe 679!

I can't dis a screen with good annualized return (and bought these), but I don't expect they'll hang around long (i.e. hit and run!)

It took a lot of searching at Zacks.com tonight to find P&P--help section under "community"--being relegated to obscurity?

Anyway, top picks today SMRT and STEC

Good investing. JW

This was a $2000 lesson for me: before trading opened yesterday I put in a stop-buy order (8.7) in Etrade and Zecco accounts for CKEC that hit my screen on Sun. Stock hit my screen but looked like it was going down. Official price range was 8.32-7.14 on >400,000 yesterday but my 8.7 stop buy was filled (!!) in both accounts at the open (high) for the day (6/16). I was told at Zecco (which quoted initially my purchase price at 8.7 last night but this AM was quoted as 8.26). I called Zecco an…